newsfilter
← Latest News
GlobeNewswire·

Amplia Therapeutics Launches First Stage of Registration-Enabling Trial of Narmafotinib

HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational studyFocus on investigating new, daily dosing of narmafotinib in combination with standard